Evidence map›Paper›PMID 41533014›Full record

ArticleMolecular diversity2026

A novel matrine derivative B10 exerts its anti-liver cancer activity in vitro and in vivo via targeting FGFR3/PI3K/AKT signaling pathway.

Xingdong Wang, Yuxin Xie, Zhouxing Hu, Siyi Wang, Manqi Li, Lichuan Wu, Jun Jiang, Lisheng Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xingdong WangSchool of Chemistry and Chemical Engineering, Guangxi University, Nanning, 530004, China.
Yuxin XieSchool of Medicine, Guangxi University, Nanning, 530004, China.
Zhouxing HuSchool of Medicine, Guangxi University, Nanning, 530004, China.
Siyi WangSchool of Medicine, Guangxi University, Nanning, 530004, China.
Manqi LiSchool of Medicine, Guangxi University, Nanning, 530004, China.
Lichuan WuSchool of Medicine, Guangxi University, Nanning, 530004, China. richard_wu@gxu.edu.cn.
Jun JiangSchool of Chemistry and Chemical Engineering, Guangxi University, Nanning, 530004, China. jiangjun@gxu.edu.cn.
Lisheng WangSchool of Medicine, Guangxi University, Nanning, 530004, China. lswang@gxu.edu.cn.

Funding

Guangxi Innovation-Driven Development Project GuiKe AA18242040the local funding project for scientific and technological development under the guidance of central government GuiKe ZY21195012
6 · The paper itself

Abstract

Natural products represent a cornerstone in anticancer drug discovery owing to their structural diversity and unique bioactivities. Among them, matrine-a principal alkaloid derived from the traditional Chinese medicine Sophora flavescens-has attracted attention due to its documented antitumor properties; however, its clinical translation has been severely hampered by inherently low potency. To address this limitation, we designed and synthesized 28 novel matrine-thiophene hybrids via a structure-based molecular hybridization approach. Notably, the lead compound B10 exhibited a dramatic enhancement in anticancer efficacy, demonstrating IC₅₀ values of 4.13-5.79 µM against hepatocellular carcinoma (HCC) cell lines, which reflects an improvement of more than 1000-fold compared to the parent matrine, while showing minimal toxicity toward normal hepatocytes. Furthermore, in an in vivo xenograft model, B10 (40 mg/kg) achieved a tumor growth inhibition rate of 64.2%, outperforming the standard drug sorafenib. Critically, to decipher the underlying mechanism, we employed a proteolysis-targeting chimera (PROTAC) strategy, converting B10 into a targeted degrader, K2. This chemical probe enabled us to identify fibroblast growth factor receptor 3 (FGFR3) as a direct target of B10 and to elucidate its role in suppressing the FGFR3/PI3K/AKT signaling pathway. Collectively, this study not only presents B10 as a highly promising candidate for HCC treatment derived from a natural product scaffold, but also identifies FGFR3 as a novel therapeutic target in HCC, thereby providing an innovative and generalizable platform for target deconvolution and mechanistic investigation of natural product-based agents.

Indexed as

AlkaloidsAntineoplastic AgentsLiver NeoplasmsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktQuinolizinesReceptor, Fibroblast Growth Factor, Type 3Signal TransductionAnimalsCell Line, TumorCell ProliferationHumansMatrinesMiceProteolysis Targeting ChimeraXenograft Model Antitumor AssaysAlkaloidsAntineoplastic AgentsMatrinesPhosphatidylinositol 3-KinasesProteolysis Targeting ChimeraProto-Oncogene Proteins c-aktQuinolizinesReceptor, Fibroblast Growth Factor, Type 3FGFR3 degradationHepatocellular carcinomaMatrine derivativesPI3K/AKT pathwayPROTAC

Identifiers

PMID41533014

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.